Case File
efta-efta00974716DOJ Data Set 9OtherFrom: Tazia Smith •tt
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00974716
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Tazia Smith •tt
>
To: "jeffrey epstein" <jeevacation®gmail.com>
Subject:
Date: Tue, 29 Oct 2013 11:24:22 +0000
Importance: Normal
Attachments: Disclaimertzt
Classification: Public
Good Morning Jeffrey - As you likely saw, AAPL recouped immediate losses in the aftermarket yday (trading back up to —527) after mgmt
comments on the conference call suggesting that lower gross margins were a result of deferrals. Will watch for any follow-through (the sell
side has been broadly positive in response to earnings) and opportunity to sell OTM calls today. Fyi only, DB's summary of AAPL's
earnings report and commentary below (reit 575 tgt).
Tazia
Tazia Smith
Director
Markets Coverage Group
Deutsche Bank Securities, Inc.
Deutsche Asset & Wealth Management
345 Park Avenue - 26th Floor
New York, NY 10154
E-mail:
From: EVS EquityFocus
Sent: 10/29/2013 10:01 AM GDT
Subject: DB: AAPL.OQ - Chris Whitmore
Classification: Public
Apple Inc (Buy, CP: $529.38, TP: $575.00, AAPL.OQ, Chris Whitmore)
Product cycles kicking Into gear
AAPL reported revs of $37.58 and EPS of $8.26 which beat expectation (vs. DB at $36.98/$8.02; Street at $36.8B/$7.93).
Apple beat on iPhone units (33.8M vs. DB at 32.5M) and iPads (14.1M vs. DB at 12M) and Mac results were light (4.6M vs.
DB at 4.8M). iPhone mix and operating leverage translated into OM (26.8% vs. DB at 26.1%) and EPS upside. AAPL will defer
-$900M in the Dec Q related to SW deferrals which impacts cash EPS but not cash flow. Consequently, we trim EPS est's but
at -8x CY14 EV/FCF we believe AAPL represents an attractive value; maintain Buy and $575 PT.
Margin guidance was solid after adjusting for software deferrals
Apple guided Dec Q revs to $55-588 which beat expectation (vs. Street at $55.58). GM's guidance of 36.5-37.5% includes
$900M of incremental software deferrals Q/Q related to including Mavericks, iLife and Work for free. We estimate —$500M of
this total is related to a change in accounting accrual per device ($5 incremental per iPhone, iPad & iPod touch unit; $20
incremental per Mac). The remaining —$400M is related to higher volume of unit shipments in the December quarter. When
EFTA00974716
comparing guidance on a like for like basis (i.e. ex the accounting change) Apple guided 4Q GM's to —38% which was in line
with Consensus on revenues of $57B +/- $1.5B which is above Consensus, suggesting improving iPhone 5S supply.
Several catalysts ahead
We expect strong holiday demand for Apple's new product lineup and suspect its guidance will prove conservative.
Furthermore, Apple remains very confident in its product pipeline heading into CY14. Specifically, we see multiple catalysts to
support growth over the next 12-18 months including iPhone 6, expansion with China Mobile and further geographic
expansion. In addition, Apple pointed to expanding into new product areas (Apple TV and/or wearables) which should alleviate
innovation concerns.
Cutting estimates to reflect accounting changes; maintain Buy and $575 PT
We adjust CY14 est's to $1808/ $43.90 (vs. prior to $184B/ $46.00) and introduce CY15 of $188B/ $48.35. Our $575 PT is
unchanged and is based on -9x CY14E EV/FCF; the lower end of its historical 7-29x range. We view the multiple as
appropriate given AAPL's growth/profit profile. Risks include product execution, ASP declines & phone / tablet comp'n.
Please click on below link for full report:
http://pull.db-gmresearch.com1p/558-2231/11731481/0900b8c0877292a9.pdf
Regards,
EVS Equity Focus
Telephone: +91-124-4622312 - 19
Please ensure all mails are also sent to our shared inbox
to avoid getting overlooked.
This email is sent to you by Evalueserve on behalf of Deutsche Bank
Diese email wurde Ihnen von Evalueserve im Auftrag der Deutschen Bank gesendet
For additional Deutsche Bank research, visit our web site: http://gm.db.com/equities
Please refer to the disclaimer that applies to the research attached in this email.
This e-mail may contain confidential and/or privileged information. If you are not the intended recipient (or have received this
e-mail in error) please notify the sender immediately and delete this e-mail. Any unauthorized copying, disclosure or
distribution of the material in this e-mail is strictly forbidden.
Please refer to http://www.db.conVen/content/eu disclosures.htm for additional EU corporate and regulatory disclosures.
This communication may contain confidential and/or privileged information.
If you are not the intended recipient (or have received this communication
in error) please notify the sender immediately and destroy this
communication. Any unauthorized copying, disclosure or distribution of the
material in this communication is strictly forbidden.
Deutsche Bank does not render legal or tax advice, and the information
contained in this communication should not be regarded as such.
EFTA00974717
Technical Artifacts (7)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
gmail.comDomain
streetaccount.comPhone
+91-124-4622312Phone
558-2231URL
http://gm.db.com/equitiesURL
http://pull.db-gmresearch.com1p/558-2231/11731481/0900b8c0877292a9.pdfURL
http://www.db.conVen/content/euRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.